US2015250865A1PendingUtilityA1

MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO

57
Assignee: VALNEVA AUSTRIA GMBHPriority: Jul 6, 2012Filed: Feb 17, 2015Published: Sep 10, 2015
Est. expiryJul 6, 2032(~6 yrs left)· nominal 20-yr term from priority
Inventors:Pär ComstedtMarkus HannerUrban LundbergAndreas MeinkeWolfgang SchülerBenjamin Wizel
A61P 31/04A61P 31/12A61P 31/10A61K 39/0225C07K 14/20A61K 39/02C12P 21/02A61K 38/00A61K 2039/6031C07K 16/12A61K 2039/55505C12N 15/70C07K 16/1207C07K 2319/00C12N 5/06C07K 2317/24A61K 2039/6018C07K 2317/55C07K 2317/54C12P 21/00Y02A50/30
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 .- 19 . (canceled) 
     
     
         20 . A polypeptide comprising a mutant OspA fragment heterodimer selected from the group consisting of Lip-S5D1-S6D1 (SEQ ID NO: 190), Lip-S6D1-S5D1 (SEQ ID NO: 196), S5D1-S6D4 (SEQ ID NO: 202) and S6D4-S5D1 (SEQ ID NO: 207). 
     
     
         21 . A polypeptide consisting of a mutant OspA fragment heterodimer selected from the group consisting of Lip-S5D1-S6D1 (SEQ ID NO: 190), Lip-S6D1-S5D1 (SEQ ID NO:
 196), S5D1-S6D4 (SEQ ID NO: 202) and S6D4-S5D1 (SEQ ID NO: 207).   
     
     
         22 . A nucleic acid coding for the polypeptide according to  claim 20 . 
     
     
         23 . A pharmaceutical composition comprising at least one of the polypeptides according to  claim 20  and optionally a pharmaceutically acceptable carrier or excipient. 
     
     
         24 . A pharmaceutical composition comprising the nucleic acid according to  claim 22  and optionally a pharmaceutically acceptable carrier or excipient. 
     
     
         25 . A pharmaceutical composition comprising Lip-S5D1-S6D1 (SEQ ID NO: 190), optionally, one or more additional mutant OspA fragment heterodimers, and optionally a pharmaceutically acceptable carrier or excipient. 
     
     
         26 . The polypeptide according to  claim 20  for use in a method for treating or protecting against a  Borrelia  infection, wherein the  Borrelia  infection is a  B. burgdorferi  s.s. or  B. afzelii  infection. 
     
     
         27 . The pharmaceutical composition according to  claim 23  for use in a method for treating or protecting against a  Borrelia  infection, wherein the  Borrelia  infection is a  B. burgdorferi  s.s. or  B. afzelii  infection. 
     
     
         28 . A pharmaceutical composition comprising the polypeptide according to  claim 21 , and optionally a pharmaceutically acceptable carrier or excipient. 
     
     
         29 . The pharmaceutical composition according to  claim 23 , wherein the pharmaceutical composition is a vaccine. 
     
     
         30 . The pharmaceutical composition according to  claim 24 , wherein the pharmaceutical composition is a vaccine. 
     
     
         31 . The pharmaceutical composition according to  claim 28 , wherein the pharmaceutical composition is a vaccine. 
     
     
         32 . The polypeptide according to  claim 21  for use in a method of treating or protecting against a  Borrelia  infection, wherein the  Borrelia  infection is a  B. burgdorferi  s.s. or  B. afzelii  infection. 
     
     
         33 . The pharmaceutical composition according to  claim 25  for use in a method of treating or protecting against a  Borrelia  infection, wherein the  Borrelia  infection is a  B. burgdorferi  s.s. or  B. afzelii  infection. 
     
     
         34 . The pharmaceutical composition according to  claim 28  for use in a method of treating or protecting against a  Borrelia  infection, wherein the  Borrelia  infection is a  B. burgdorferi  s.s. or  B. afzelii  infection. 
     
     
         35 . A method of treating or preventing a  Borrelia  infection in a subject in need thereof comprising the step of administering to the subject a therapeutically-effective amount of a polypeptide according to  claim 20 . 
     
     
         36 . A method of treating or preventing a  Borrelia  infection in a subject in need thereof comprising the step of administering to the subject a pharmaceutical composition according to  claim 23 . 
     
     
         37 . A method for producing a polypeptide according to  claim 20 , characterized by the following steps:
 a) introducing a vector encoding the polypeptide into a host cell,   b) growing the host cell under conditions allowing for expression of said polypeptide,   c) homogenizing said host cell, and   d) subjecting the host cell homogenate to purification steps.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.